loading page

Coronavirus Disease 2019 (COVID-19) and its neuroinvasive capacity: Is it time for melatonin?
  • +3
  • Alejandro Romero,
  • Eva Ramos,
  • Francisco López Muñoz,
  • Emilio Gil-Martín,
  • Germaine Escames,
  • Russ Reiter
Alejandro Romero
Complutense University of Madrid
Author Profile
Eva Ramos
Complutense University of Madrid
Author Profile
Francisco López Muñoz
Camilo Jose Cela University
Author Profile
Emilio Gil-Martín
University of Vigo Faculty of Biology
Author Profile
Germaine Escames
University of Granada
Author Profile
Russ Reiter
University of Texas UTHSCSA
Author Profile


The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spread throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination have confirmed the presence of the virus in neural tissue. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.

Peer review status:Published

09 Aug 2020Published in Cellular and Molecular Neurobiology. 10.1007/s10571-020-00938-8